Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.

被引：0
|
作者：
Wainberg, Zev A.
Bendell, Johanna C.
Lenz, Heinz-Josef
Baron, Ari David
Berlin, Jordan
Bessudo, Alberto
Bruetman, Daniel
Chung, Ki Y.
Park, Haeseong
Patel, Manish R.
Adewoye, Adeboye H.
Liu, JieJane
Patel, Ravindranath
Shah, Manish A.
机构：
[1] UCLA, David Geffen Sch Med, Los Angeles, CA USA
[2] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[3] USC, Keck Sch Med, Los Angeles, CA USA
[4] Calif Pacif Med Ctr Res Inst, San Francisco, CA USA
[5] Vanderbilt Univ, Ingram Canc Ctr, Nashville, TN USA
[6] Calif Canc Care Associates Res & Excellence, Encinitas, CA USA
[7] Goshen Ctr Canc Care, Goshen, IN USA
[8] Greenville Hlth Syst Canc Inst, Greenville, SC USA
[9] Washington Univ, Sch Med, St Louis, MO USA
[10] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA
[11] Gilead Sci Inc, Foster City, CA USA
[12] Comprehens Blood & Canc Ctr, Bakersfield, CA USA
[13] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3578
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Vera Gorbunova
    J. Thaddeus Beck
    Ralf-Dieter Hofheinz
    Pilar Garcia-Alfonso
    Marina Nechaeva
    Antonio Cubillo Gracian
    Laszlo Mangel
    Elena Elez Fernandez
    Dustin A. Deming
    Ramesh K. Ramanathan
    Alison H. Torres
    Danielle Sullivan
    Yan Luo
    Jordan D. Berlin
    British Journal of Cancer, 2019, 120 : 183 - 189
  • [42] Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab: Results of the expansion part of a phase I study in patients with metastatic colorectal cancer
    Bordonaro, Roberto
    Calvo, Aitana
    Auriemma, Alessandra
    Hollebecque, Antoine
    Rubovszky, Gabor
    Saunders, Mark P.
    Papai, Zsuzsanna
    Prager, Gerald W.
    Stein, Alexander
    Andre, Thierry
    Argiles, Guillem
    Cubillo, Antonio
    Dahan, Laetitia
    Edeline, Julien
    Leger, Catherine
    Amellal, Nadia
    Cattan, Valerie
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [43] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
    Ting Deng
    Le Zhang
    Xiao-jian Liu
    Jian-ming Xu
    Yu-xian Bai
    Yan Wang
    Yu Han
    Yu-hong Li
    Yi Ba
    Medical Oncology, 2013, 30
  • [44] Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment
    Odabas, H.
    Ozdemir, N.
    Isik, M.
    Abali, H.
    Oksuzoglu, B.
    Kos, T.
    Civelek, B.
    Babacan, A. N.
    Dogan, U.
    Zengin, N.
    JOURNAL OF BUON, 2011, 16 (03): : 460 - 463
  • [45] COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE
    Gyldmark, M.
    Aultman, R.
    Siebert, U.
    Sabate, E.
    VALUE IN HEALTH, 2009, 12 (03) : A49 - A49
  • [46] Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study
    Deng, Ting
    Zhang, Le
    Liu, Xiao-jian
    Xu, Jian-ming
    Bai, Yu-xian
    Wang, Yan
    Han, Yu
    Li, Yu-hong
    Ba, Yi
    MEDICAL ONCOLOGY, 2013, 30 (04)
  • [47] A phase I study of sorafenib with FOLFIRI as first-line therapy for metastatic colorectal cancer (mCRC): Safety and efficacy results
    Maroun, Jean Alfred
    Jonker, Derek J.
    Cripps, M. Christine
    Asmis, Timothy R.
    Goel, Rakesh
    Goodwin, Rachel Anne
    Marginean, Horia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J. C.
    Tournigand, C.
    Bednarczyk, M.
    Swieboda-Sadlej, A.
    Chung, I.
    Barone, C.
    Tarazi, J. C.
    Rosbrook, B.
    Ricart, A. D.
    Sobrero, A. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [49] SORAFENIB (S) WITH FOLFIRI AS FIRST LINE THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC): A PHASE I STUDY
    Maroun, J. A.
    Jonker, D. J.
    Asmis, T.
    Cripps, C.
    Goel, R.
    Yarom, N.
    Vickers, M. M.
    Marginean, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 200 - 200
  • [50] Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
    Song Xie
    Guoping Han
    Zhikun Fan
    Lifeng He
    Wenbing Xu
    Zhen Qin
    Medical Oncology, 2014, 31
12345